DSpace Fukushima Medical University

福島県立医科大学学術成果リポジトリ = Fukushima Medical University Repository >
福島医学会 = The Fukushima Society of Medical Science >
Fukushima Journal of Medical Science >
Vol.56 (2010) >

Please use this identifier to cite or link to this item: http://ir.fmu.ac.jp/dspace/handle/123456789/256

Files in This Item:

File Description SizeFormat
FksmJMedSci_56_p1.pdf1.35 MBAdobe PDFDownload
Title: Attenuation of ischemic myocardial injury and dysfunction by cardiac fibroblast-derived factor(s)
Other Titles: Cardio protection by cardiac fibroblasts
Authors: Nakazato, Kazuhiko
Naganuma, Wakako
Ogawa, Kazuei
Yaoita, Hiroyuki
Mizuno, Shinya
Nakamura, Toshikazu
Maruyama, Yukio
Affiliation: 循環器・血液内科学講座
Source title: Fukushima Journal of Medical Science
Volume: 56
Issue: 1
Start page: 1
End page: 16
Issue Date: Jun-2010
Abstract: Fibroblasts, the majority of non-cardiomyocytes in the heart, are known to release several kinds of substances such as cytokines and hormones that affect cell and tissue functions. We hypothesized that undefined substance (s) derived from cardiac fibroblasts may have the potential to protect against ischemic myocardium. To assess our hypothesis, using rats, we investigated: (1) the effect of cardiac fibroblast-conditioned medium (CM) on the viability of hypoxic cardiomyocytes in vitro, (2) the effect of CM on left ventricular (LV) function in global ischemia-reperfusion in an ex vive model, (3) the mechanism underlying cardioprotection by CM. Seventy-two hours after starting a hypoxic culture, the viability of cardiomyocytes was higher (P < 0.05) in the CM treated group (41.4%) compared to the control (20.5%). In Langendorff's preparation, 30 min after ischemia-reperfusion, LV end-diastolic pressure was lower, and LV developed pressure and -LVdP/dt were higher (P < 0.01 or P < 0.05) in the CM group than in the control, although coronary flow did not differ between the two groups. Pretreatment with a protein kinase C inhibitor or a mitochondrial ATP-sensitive K+ channel blocker attenuated these changes of LV function in the CM group. Such cardioprotection was achieved by a fraction of the CM having a molecular weight (MW) > 50,000, but not by that of the CM with a lower MW. In addition, a specific antibody against hepatocyte growth factor (HGF, MW is 84,000) did not reduce the cardioprotection afforded by CM. There may be an unknown cardioprotective substance other than HGF in rats, which mimics ischemic preconditioning and has MW > 50,000.
Publisher: The Fukushima Society of Medical Science
Publisher (Alternative foam): 福島医学会
language: eng
URI: http://ir.fmu.ac.jp/dspace/handle/123456789/256
Full text URL: http://ir.fmu.ac.jp/dspace/bitstream/123456789/256/1/FksmJMedSci_56_p1.pdf
ISSN: 0016-2590
DOI: 10.5387/fms.56.1
PubMed ID: 21485651
Other version: http://dx.doi.org/10.5387/fms.56.1
Rights: © 2010 The Fukushima Society of Medical Science
Appears in Collections:Vol.56 (2010)

Files in This Item:

File Description SizeFormat
FksmJMedSci_56_p1.pdf1.35 MBAdobe PDFDownload

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard